Literature DB >> 10364771

New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

R C Becker1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10364771     DOI： 10.1023/a:1008845822884

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  106 in total

1.  Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

Authors:  S P Schulman; P J Goldschmidt-Clermont; E J Topol; R M Califf; F I Navetta; J T Willerson; N C Chandra; A D Guerci; J J Ferguson; R A Harrington; A M Lincoff; S J Yakubov; P F Bray; R D Bahr; C L Wolfe; P G Yock; H V Anderson; T W Nygaard; S J Mason; M B Effron; A Fatterpacker; S Raskin; J Smith; L Brashears; P Gottdiener; C du Mee; M M Kitt; G Gerstenblith
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

2.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.

Authors:  C P Cannon; C M Gibson; C H McCabe; A A Adgey; M J Schweiger; R F Sequeira; G Grollier; R P Giugliano; M Frey; H S Mueller; R M Steingart; W D Weaver; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

3.  Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.

Authors:  D Hoppensteadt; A Racanelli; J M Walenga; J Fareed
Journal:  Semin Thromb Hemost       Date:  1989-10       Impact factor: 4.180

Review 4.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

Review 5.  Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

Authors:  R A Harrington
Journal:  Am J Cardiol       Date:  1997-08-18       Impact factor: 2.778

6.  Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.

Authors:  V V Kakkar; W J Murray
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

7.  Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.

Authors:  M Koller; U Schoch; P Buchmann; F Largiadèr; A von Felten; P G Frick
Journal:  Thromb Haemost       Date:  1986-12-15       Impact factor: 5.249

8.  Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.

Authors:  H R Lijnen; J M Stassen; I Vanlinthout; H Fukao; K Okada; O Matsuo; D Collen
Journal:  Thromb Haemost       Date:  1991-10-01       Impact factor: 5.249

9.  Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

Authors:  H N Magnani
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

10.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.